How Do I Manage a Patient With Myelofibrosis and Severe Anemia?

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Responding to Unmet Needs in Myelofibrosis: Post-Ruxolitinib Treatment and Managing Cytopenic Myelofibrosis

How Do I Manage a Patient With Myelofibrosis and Severe Anemia?

ReachMD Healthcare Image
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.25 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
  • Overview

    The lack of a consensus definition of ruxolitinib failure, combined with a growing number of treatment options, adds to the challenges facing clinicians (hematologists, hematologist-oncologists, and advanced practice providers) who treat patients with primary myelofibrosis. These include expeditiously recognizing intolerance or treatment resistance with ruxolitinib and then selecting and transitioning patients to the most appropriate next therapy for each patient. This program provides data-driven expert guidance to help clinicians promptly identify ruxolitinib failure, select next-line therapy based on patient-specific clinical needs and preferences, and apply best practices for safely transitioning from ruxolitinib to next therapy and management of AEs. It also provides recommendations on engaging patients to share in treatment decisions that address their symptoms and reflect their preferences regarding their quality of life.

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, including hematologists/oncologists as well as other clinicians involved in the management of patients with myelofibrosis.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Apply the latest scientific evidence and best practices to inform strategies to identify and overcome ruxolitinib failure
    • Apply the latest scientific evidence and best practices to inform strategies to manage myelofibrosis-associated cytopenias
    • Recognize and manage common AEs events associated with JAK inhibitor therapies
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change.

  • Faculty Disclosure of Commercial Relationships

    Disclosure Policy
    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs.

    The following faculty have disclosed:

    John Mascarenhas, MD, faculty for this educational event, receives research funds from Incyte, Novartis, CTI Bio, Geron, Kartos, BMS, Abbvie, Merck, and Roche; and receives consulting fees from Incyte, Novartis, PharmaEssentia, Roche, CTI Bio, Sierra Onc, GSK, Geron, Kartos, Abbvie, Galecto, BMS, Morphosys and Karyopharm.

    Srdan Verstovsek, MD, PhD, faculty for this educational event, receives research funds from Incyte Corporation, Roche, NS Pharma, Celgene, Gilead, CTI BioPharma, Genentech, Blueprint Medicines, Novartis, Sierra Oncology, PharmaEssentia, AstraZeneca, Italfarmaco and Protagonist; and receives consulting fees from Constellation, Sierra, Incyte, Novartis, Celgene, and BMS.

  • Planners and Managers Disclosure List

    The following planners/reviewers/managers have disclosed:

    Robert Garris, PharmD, MPH, planner for this educational event, has no relevant financial relationships with ineligible companies.

    William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.

    TotalCME, Inc. planners and managers have no relevant commercial relationships to disclose.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Acknowledgment

    This activity is supported by independent educational grants from Sierra Oncology, Inc. and CTI BioPharma Corp.

    Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.

  • Fee Statements

    This activity is FREE to all participants.

  • Instructions for Completion

    During the period 12/22/2022 through 12/22/2023, registered participants wishing to receive continuing education credit for this activity must follow these steps:

    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%.
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule22 Sep 2023